Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-23
2010-10-19
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S313000, C514S314000, C546S159000, C546S161000
Reexamination Certificate
active
07816372
ABSTRACT:
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR. Also provided are methods of making such compounds and pharmaceutical compositions.
REFERENCES:
patent: 3847988 (1974-11-01), Gold
patent: 3928686 (1975-12-01), Poot et al.
patent: 3979394 (1976-09-01), Janssens et al.
patent: 4066651 (1978-01-01), Brittain et al.
patent: 4097578 (1978-06-01), Perronnet et al.
patent: 4138490 (1979-02-01), Brittain et al.
patent: 4202895 (1980-05-01), Inaba et al.
patent: 4415572 (1983-11-01), Tominaga et al.
patent: 4505852 (1985-03-01), Rasnick et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4710507 (1987-12-01), Campbell et al.
patent: 4728653 (1988-03-01), Campbell et al.
patent: 4933336 (1990-06-01), Martin et al.
patent: 4981784 (1991-01-01), Evans et al.
patent: 5071773 (1991-12-01), Evans et al.
patent: 5081242 (1992-01-01), Combs
patent: 5576324 (1996-11-01), Kyotani et al.
patent: 5677336 (1997-10-01), Jones et al.
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5977108 (1999-11-01), Kikuchi et al.
patent: 5994544 (1999-11-01), Jones et al.
patent: 6017924 (2000-01-01), Edwards et al.
patent: 6093821 (2000-07-01), Jones et al.
patent: 6121450 (2000-09-01), Jones et al.
patent: 6180794 (2001-01-01), Edwards et al.
patent: 6340704 (2002-01-01), Marui et al.
patent: 6358948 (2002-03-01), Zhang et al.
patent: 6380207 (2002-04-01), Coghlan et al.
patent: 6448405 (2002-09-01), Jones et al.
patent: 6462038 (2002-10-01), Higuchi et al.
patent: 6498154 (2002-12-01), Grubb et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6534516 (2003-03-01), Edwards et al.
patent: 6566372 (2003-05-01), Zhi et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6635759 (2003-10-01), Uray et al.
patent: 6667313 (2003-12-01), Hamann et al.
patent: 6673799 (2004-01-01), Taniguchi et al.
patent: 6696459 (2004-02-01), Jones et al.
patent: 6964973 (2005-11-01), Zhi et al.
patent: 7071205 (2006-07-01), Zhi et al.
patent: 7084151 (2006-08-01), Zhi et al.
patent: 7214690 (2007-05-01), Higuchi et al.
patent: 2002/0094983 (2002-07-01), Zhang et al.
patent: 2002/0183314 (2002-12-01), Higuchi et al.
patent: 2002/0183346 (2002-12-01), Zhi et al.
patent: 2003/0045511 (2003-03-01), Grubb et al.
patent: 2003/0055094 (2003-03-01), Sun et al.
patent: 2003/0149268 (2003-08-01), Hamann et al.
patent: 2003/0186970 (2003-10-01), Higuchi et al.
patent: 2003/0216388 (2003-11-01), Zhang et al.
patent: 2003/0216428 (2003-11-01), Miyakawa et al.
patent: 2004/0186132 (2004-09-01), Jones et al.
patent: 2005/0288350 (2005-12-01), Zhi et al.
patent: 2334738 (1975-01-01), None
patent: 3810706 (1989-10-01), None
patent: 0272910 (1988-06-01), None
patent: 0356230 (1990-02-01), None
patent: 0542609 (1993-05-01), None
patent: 0638571 (1995-02-01), None
patent: 89/07441 (1989-08-01), None
patent: 94/23068 (1994-10-01), None
patent: 96/19458 (1996-06-01), None
patent: 96/41013 (1996-12-01), None
patent: 97/49709 (1997-12-01), None
patent: 99/58486 (1999-11-01), None
patent: 00/66680 (2000-11-01), None
patent: 01/16108 (2001-03-01), None
patent: 01/16133 (2001-03-01), None
patent: 01/16139 (2001-03-01), None
patent: 01/27086 (2001-04-01), None
patent: WO 02/16310 (2002-02-01), None
patent: 02/22585 (2002-03-01), None
patent: 02/066475 (2002-08-01), None
patent: 02/068427 (2002-09-01), None
patent: 03/037905 (2003-05-01), None
patent: WO 03/090672 (2003-11-01), None
patent: 2004/045518 (2004-06-01), None
patent: 2005/018573 (2005-03-01), None
patent: 2005/090282 (2005-09-01), None
patent: 016108 (2009-03-01), None
patent: WO 2009/082437 (2009-07-01), None
Alabaster, et al., “2(1H)-quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives.” J. Med. Chem., 32:575-583 (1989).
Bains & Tacke, “Silicon chemistry as a novel source of chemical diversity in drug design,” Curr. Opin. Drug Discov. Devel. 6:526-43 (2003).
Berger et al., “Interaction of glucocorticoid analogues with the human glucocorticoid receptor,” J. Steroid Biochem. Mol. Biol., 41: 733-738 (1992).
Bissell et al., “Synthesis and Chemistry of 7-Amino-4- (trifluoromethyl) coumarin and Its Amino Acid and Peptide Derivatives,” J. Org. Chem., 45(12):2283-2287 (1980).
Certified English translation of German patent, DE 3810706 published Oct. 5, 1989 entitled “Substituted Cumarine Derivatives, Method for their Production, and Their Use As an Application with an herbicide Effect.”
Croston, G. E., Milan, L. B., Marschke, K. B., Reichman, M. and Briggs, M. R. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes Endocrinology 138(9):3779-3786 (1997).
Derwert citing French patent EP 0542609 published May 19, 1993, for: “New 3-sulphonylamino-2(1H)-quinolinone derivs.- as excitatory aminoacid receptor blockers for treating cerebrovascular accident, spinal trauma, amyotrophic lateral sclerosis, Alzheimer's disease and schizophrenia.”
Derwert citing German patent DE 2334738 published Jan. 1, 1975, for: “Hair-dyestuff for oxidation-dyeing process-contg. 4 hydroxy-quinolone-2-derivs. as coupling components.”
Derwert citing German patent, DE 3810706 published Oct. 5, 1989, for: “New coumarin derivs. contg, imide gp.- useful as selective herbicides.”
Derwert citing Japanese patent WO 01/27086 published Apr. 19, 2001, for: “New tetrahydroquinoline derivatives useful as androgen receptor binding agents for treating e.g. males sexual dysfunction.”
Edwards, et al., “5-Aryl-1,2-dihydro-5H-chromeno [3,4-f] quinolines as Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists: The Effect of D-Ring Substitutes,”Journal of Medicinal Chem. 41:303-310 (1998).
Edwards, et al., “New nonsteroidal androgen receptor modulators based on4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone,” Bioorg Med Chem Lett.,8(7)745-50 (1998).
Edwards, et al., “Nonsteroidal androgen receptor agonists based on4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one,” Bioorg Med Chem Lett., 9(7)1003-8 (1999).
Edwards, et al., “Preparation, Resolution, and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists,”Journal of Medicinal Chem. 41:2779-85 (1998).
Evans, et al., “The Steroid and Thyroid Hormone Receptor Superfamily,” Science, 240:889-895 (1998).
Fingl et al. “The Pharmacological Basis of Therapeutics”, Ch.1 p. 1 (1975).
Hamann, et al, “Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)” J Med Chem., 42(2):210-2 (1999).
Hamann, et al. “Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.,” J. Med. Chem., 41(4) 623-639 (1998).
Hamann, et al., “Nonsteroidal progesterone receptor antagonists based on aconformationally-restricted subseries of6-aryl-1,2-dihydro-2,2,4-trimethylquinolines,” Bioorg Med Chem Lett., 8(19)2731-6(1998).
Higuchi, et al., “4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolinespotent, nonsteroidal androgen receptor agonists.” Bioorg Med Chem Lett., 9(9)1335-40.(1999).
Kong, et al., “Effects of isosteric pyridone replacements in androgen receptor antagonistsbased on 1,2-dihydro- and1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quinolines,” Bioorg Med Chem Lett., 10(5)411-
Lau Thomas Lot Stevens
Long Yun Oliver
Martinborough Esther
Shen Yixing
Wu Min
K & L Gates LLP
Ligand Pharmaceuticals Incorporated
Miskiel Frank J.
Seaman D. Margaret
Seidman Stephanie
LandOfFree
6-cycloamino-2-quinolinone derivatives as androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 6-cycloamino-2-quinolinone derivatives as androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-cycloamino-2-quinolinone derivatives as androgen receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174348